Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that long-term recombinant interferon alpha-2b therapy was associated with considerable hair loss in some patients, indicated by a telogen effluvium pattern on trichograms.

This study found that recombinant IFN α-2b injections in patients with acute post-transfusion hepatitis C can suppress viral RNA and lead to normalization of serum ALT, though long-term prevention of chronicity remains unclear.

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

During treatment with interferon/ribavirin for hepatitis C, this study observed significant and lasting improvement in a patient's psoriasis without additional psoriasis-specific therapies.

This study found that injecting interferon gamma into C3H/HeJ mice did not alter the frequency or onset of alopecia areata, suggesting the protein alone does not trigger the disease.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

In this study, researchers developed a rapid platform using primary human lung tissues to identify SARS-CoV-2 targets and test antiviral compounds, achieving highly reproducible results across viral variants.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.

In this study, Typhonium flagelliforme leaf-ethanolic extract combined with natural interferon was observed to stabilize body weight, inhibit tumor growth, and reduce mitosis, angiogenesis, and certain protein expressions in carcinogen-induced tumors in female mice, suggesting potential antitumor effects.

This review discusses the potential of organoids in modeling COVID-19 disease and developing therapies, without reporting new results, and highlights opportunities and challenges in their application for research.

This study found that recombinant hepatitis B vaccine may increase the risk of alopecia areata onset in older predisposed mice but larger trials suggest this effect might lie within normal variation.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This article discusses the side effects of interferon beta therapy for MS, including flu-like symptoms and autoimmune reactions, and provides guidance on their management but does not report new clinical findings.

This study found that cutaneous ulcers caused by interferon are not associated with the medication's dosage.

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.

In this study, researchers developed a new photoactivatable Cre recombinase mouse model, DiLiCre, which allows precise light-induced genetic modifications and cell tracing, demonstrating its effectiveness for advancing biological and biomedical research.

This study found that certain nutraceuticals did not interfere with tamoxifen's inhibition of estrogen in breast cancer cells and may enhance its effects, suggesting potential as an adjuvant therapy for hair loss in patients undergoing endocrine therapy.

This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.